| European Case Law Identifier: | ECLI:EP:BA:2009:T076406.20090225 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date of decision: | 25 February 2009 | ||||||||
| Case number: | T 0764/06 | ||||||||
| Petition for review: | R 0016/09 | ||||||||
| Application number: | 96924368.2 | ||||||||
| IPC class: | C07D 207/34 | ||||||||
| Language of proceedings: | EN | ||||||||
| Distribution: | C | ||||||||
| Download and more information: |
|
||||||||
| Title of application: | Crystalline R-(R*,R*)-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-(phenylamino)carbonyl-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) | ||||||||
| Applicant name: | Warner-Lambert Company LLC | ||||||||
| Opponent name: | Teva Pharmaceutical Industries Ltd. LEK Pharmaceutical and Chemical Company d.d. |
||||||||
| Board: | 3.3.01 | ||||||||
| Headnote: | - | ||||||||
| Relevant legal provisions: |
|
||||||||
| Keywords: | Admissibility of allegedly new ground of opposition (yes) Added matter (yes) - Omission of an essential feature Late-filed request (not admitted) |
||||||||
| Catchwords: |
- |
||||||||
| Cited decisions: |
|
||||||||
| Citing decisions: |
|
||||||||
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t060764eu1.html
Date retrieved: 17 May 2021